Hypomyelinating Leukodystrophy 2

Genetic MONDO:0012125 Pathograph 38 Show in embeddings browser Leukodystrophy

Autosomal recessive hypomyelinating leukodystrophy caused by biallelic GJC2 variants. GJC2 encodes connexin-47 (Cx47), the gap-junction protein that couples oligodendrocytes to astrocytes (through Cx47/Cx43 channels) and to each other. The disease is the autosomal recessive phenocopy of Pelizaeus-Merzbacher disease: nystagmus beginning in the neonatal or early-infantile period, hypotonia that evolves into spasticity, cerebellar signs in childhood, and diffuse CNS hypomyelination on MRI, usually with normal cognition or mild intellectual disability and a slowly progressive course. Two mechanisms are documented for the same protein. Most coding alleles abolish channel function, and several (p.P87S, p.Y269D, p.M283T) are also retained in the endoplasmic reticulum, where in primary oligodendrocytes they switch on the unfolded protein response and apoptotic pathways. A recurrent promoter variant (c.-167A>G) instead removes a SOX10 binding site and lowers GJC2 transcription. The milder allelic disorder, spastic paraplegia 44, is curated separately.

Ask OpenScientist

Ask a research question about Hypomyelinating Leukodystrophy 2. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

👪

Inheritance

1
Autosomal recessive HP:0000007
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"PMLD1 is inherited in an autosomal recessive manner."
GeneReviews states the mode of inheritance.
⚙

Pathophysiology

8
Biallelic GJC2 Loss of Function
Biallelic GJC2 variants remove connexin-47 channel function from oligodendrocytes. Missense, nonsense and frameshift alleles were found in the founding families. Expressed in cell lines, the missense alleles P87S, Y269D and M283T form no functional channels. The recurrent promoter variant c.-167A>G acts upstream of the protein, abolishing a SOX10 binding site and lowering promoter activity.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
GJC2 hgnc:17494 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GJC2 (hgnc:17494). hgnc:17494 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context variant_origin: GERMLINE functional_impact_category: LOSS_OF_FUNCTION
connexin-47 gap junction channel activity GO:0005243 ⇓ LOSS OF FUNCTION Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves connexin-47 gap junction channel activity, annotated with gap junction channel activity (GO:0005243), qualified as loss of function. GO:0005243 is a molecular function from the Gene Ontology.
Downstream
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
Connexin-47 ER Retention and Unfolded Protein Response Applies to the ER-retained missense alleles, not to the promoter variant or to truncating alleles.
Show evidence (3 references)
PMID:15192806 SUPPORT Human Clinical
"In three of six families with PMLD, we detected five different GJA12 mutations, including missense, nonsense, and frameshift mutations."
The founding gene discovery, in human families.
PMID:17344063 SUPPORT In Vitro
"Dual whole-cell patch clamping of transfected Neuro2A cells demonstrated that none of the mutants formed functional channels, in contrast to wild type Cx47."
Shows directly that three patient missense alleles are channel-dead.
PMID:20695017 SUPPORT In Vitro
"Functionally, this mutation completely abolished the SOX10 binding and attenuated GJC2 promoter activity."
Establishes the transcriptional route to loss of function for the promoter variant.
Connexin-47 ER Retention and Unfolded Protein Response
Several PMLD1 missense proteins are retained in the endoplasmic reticulum instead of reaching the plasma membrane. In primary oligodendrocytes, three such mutants activate the unfolded protein response and apoptotic pathways, a toxic gain of function on top of channel loss. The milder SPG44 allele p.I33M traffics normally and activates neither, which is one measured difference between the severe and mild ends of the GJC2 spectrum.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
unfolded protein response GO:0030968 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased unfolded protein response, annotated with endoplasmic reticulum unfolded protein response (GO:0030968). GO:0030968 is a biological process from the Gene Ontology.
Downstream
Oligodendrocyte Apoptosis
Show evidence (2 references)
PMID:35276347 SUPPORT In Vitro
"Here we show that when expressed in primary OLs, three PMLD1 associated mutants (p.P87S, p.Y269D and p.M283T) show ER retention of Cx47 and evidence of activation of the cellular stress (unfolded protein response, UPR) and apoptotic pathways."
Primary-oligodendrocyte evidence for ER retention and UPR activation.
PMID:20442743 SUPPORT In Vitro
"The mutants T265A and A98G_V99insT were retained in the ER, T398I formed gap junctional plaques at the plasma membrane, and G149S showed both, structures at the plasma membrane and ER localization."
ER retention is allele-specific; one mutant reaches the membrane, which is why this branch does not cover every allele.
Oligodendrocyte Apoptosis
Death of oligodendrocytes downstream of ER stress in cells carrying ER-retained mutants, and in the Cx32/Cx47 double-knockout mouse, where restoring Cx47 to oligodendrocytes reduces it.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
apoptotic process GO:0006915 ↑ INCREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology.
Downstream
CNS Hypomyelination
Show evidence (2 references)
PMID:35276347 SUPPORT In Vitro
"These studies provide new insight into a potential element of toxic gain of function underlying the mechanism of PMLD1"
The authors frame the apoptotic activation as a candidate toxic gain-of-function mechanism, with their hedge kept.
PMID:12843301 SUPPORT INDIRECT Model Organism
"animals lacking both connexins die by postnatal week 6 from profound abnormalities in central myelin, characterized by thin or absent myelin sheaths, vacuolation, enlarged periaxonal collars, oligodendrocyte cell death, and axonal loss."
Oligodendrocyte death in the double-knockout mouse. INDIRECT because the genotype removes Cx32 as well as Cx47.
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
Oligodendrocytes couple to astrocytes through heterotypic Cx47/Cx43 and Cx32/Cx30 channels. PMLD1 mutants fail to form functional channels with astrocytic Cx43, and a knock-in mouse carrying the orthologue of human M283T loses most glial network coupling in the corpus callosum, as Cx47-null mice do. Loss of this panglial network, rather than of Cx47 protein as such, is the proposed core of the disease.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology. astrocyte CL:0000127 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves astrocyte (CL:0000127). CL:0000127 is a cell type from the Cell Ontology.
heterotypic Cx47/Cx43 gap junction channel activity GO:0005243 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased heterotypic Cx47/Cx43 gap junction channel activity, annotated with gap junction channel activity (GO:0005243). GO:0005243 is a molecular function from the Gene Ontology.
oligodendrocyte-astrocyte gap junction GO:0005921 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves oligodendrocyte-astrocyte gap junction, annotated with gap junction (GO:0005921). GO:0005921 is a cellular component from the Gene Ontology.
Animal models
Cx47 M282T knock-in mouse Mouse recapitulates Carries a patient-derived allele and loses most glial network coupling.
Downstream
Impaired Potassium Spatial Buffering
CNS Hypomyelination
Microglial Activation and White Matter Inflammation
Show evidence (2 references)
PMID:18094232 SUPPORT In Vitro
"Finally, Cx47 mutants that cause Pelizaeus-Merzbacher-like disease do not efficiently form functional channels with Cx43, indicating that disrupted Cx47/Cx43 channels cause this disease."
Identifies the heterotypic oligodendrocyte-astrocyte channel as the one the patient mutants lose.
PMID:21750683 SUPPORT Model Organism
"10-15-day-old homozygous Cx47M282T and Cx47 null mice revealed a more than 80% reduction in the number of cells participating in glial networks after biocytin injections into oligodendrocytes in sections of corpus callosum."
In vivo loss of glial network coupling with a patient-derived allele.
Impaired Potassium Spatial Buffering
Oligodendrocyte connexins take part, with the astrocytic K+ channel Kir4.1, in clearing the K+ released by active axons. Without them, myelin develops vacuoles whose size and number track axonal activity. Shown in mice lacking both oligodendrocyte connexins; how much this contributes in human HLD2 is not established.
potassium ion homeostasis GO:0055075 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased potassium ion homeostasis (GO:0055075). GO:0055075 is a biological process from the Gene Ontology.
Downstream
CNS Hypomyelination Activity-dependent myelin vacuolation contributes to the unstable sheath.
Show evidence (2 references)
PMID:17065440 SUPPORT INDIRECT Model Organism
"The size and number of myelin vacuoles was dramatically increased when axonal activity was increased, by either a natural stimulus (eye opening) or pharmacological treatment."
Activity dependence of the myelin lesion in Cx32/Cx47 double-knockout mice. INDIRECT because the genotype also removes Cx32.
PMID:17065440 SUPPORT INDIRECT Model Organism
"Together, these results implicate oligodendrocytes and their connexins as having critical roles in the buffering of K+ released during neuronal activity."
The authors' conclusion tying the connexins to K+ buffering.
Microglial Activation and White Matter Inflammation
In mice lacking both oligodendrocyte connexins, the affected cerebellum shows activated microglia and astrocytes and infiltrating T and B cells, alongside reduced expression of myelin-lipid synthesis genes. Human neuropathology to confirm this arm is not available.
microglial cell CL:0000129 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves microglial cell (CL:0000129). CL:0000129 is a cell type from the Cell Ontology.
Downstream
CNS Hypomyelination
Show evidence (1 reference)
PMID:26051537 SUPPORT Model Organism
"In accord, immunostaining showed T- and B-cells in the cerebella of mutant mice as well as activated microglia and astrocytes."
Immune and glial activation in the double-knockout model.
CNS Hypomyelination
The tissue-level lesion: CNS myelin is deficient from the start, seen on MRI as diffuse hypomyelination. In mice the lesion appears as vacuolated myelinated fibres with Cx47 loss alone and as thin or absent sheaths when Cx32 is also removed.
central nervous system myelination GO:0022010 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased central nervous system myelination (GO:0022010). GO:0022010 is a biological process from the Gene Ontology.
Animal models
Cx32/Cx47 double-knockout mouse Mouse recapitulates
Cx47 M282T knock-in mouse Mouse fails to recapitulate
Toy Poodle GJC2 frameshift hypomyelinating leukodystrophy Dog recapitulates Naturally occurring canine GJC2 disease with white matter vacuolation and demyelination.
Downstream
CNS hypomyelination on MRI
Nystagmus
Hypotonia
Motor delay
Speech delay
Dysarthria
Spasticity
Gait ataxia
Dysmetria
Intention tremor
Head titubation
Dysdiadochokinesia
Mild intellectual disability
Seizures
Choreoathetosis
Dystonia
Optic atrophy
Hearing loss
Dysphagia GeneReviews attributes swallowing difficulty to the motor impairment.
Show evidence (2 references)
PMID:15192806 SUPPORT Human Clinical
"In this study, we demonstrate that GJA12 plays a key role in central myelination and is involved in peripheral myelination in humans."
The founding authors' conclusion from the human families.
PMID:12805295 SUPPORT Model Organism
"Electron microscopic analysis of CNS white matter in Cx47-deficient mice revealed a conspicuous vacuolation of nerve fibers, particularly at the site of the optic nerve where axons are first contacted by oligodendrocytes and myelination starts."
Myelin pathology attributable to Cx47 loss alone.
Peripheral Nerve Myelin Involvement
Unlike in mice, GJC2 is transcribed in human peripheral nerve, and some patients have slowed nerve conduction consistent with a mild demyelinating neuropathy. It is a minority finding (2 of 10 patients in one neurophysiology series).
Downstream
Demyelinating peripheral neuropathy
Show evidence (1 reference)
PMID:15192806 SUPPORT Human Clinical
"These results are in accordance with the electrophysiological finding of reduced motor and sensory nerve conduction velocities in patients with PMLD, which argues for a demyelinating neuropathy."
Human peripheral nerve conduction findings.
⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hypomyelinating Leukodystrophy 2 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

22
Digestive 1
Dysphagia HP:0002015 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Swallowing difficulty, annotated with Dysphagia (HP:0002015). HP:0002015 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Motor impairments can lead to swallowing difficulty and orthopedic complications, including hip dislocation and scoliosis."
Swallowing difficulty is a consequence of the motor impairment.
Ear 1
Hearing loss VERY_RARE Hearing impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hearing loss, annotated with Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Hearing loss and optic atrophy are observed in rare cases."
Hearing loss is a rare finding.
Eye 2
Nystagmus VERY_FREQUENT HP:0000639 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Nystagmus (HP:0000639). HP:0000639 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
Nystagmus is the typical presenting sign.
Optic atrophy VERY_RARE HP:0000648 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Optic atrophy (HP:0000648). HP:0000648 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Hearing loss and optic atrophy are observed in rare cases."
Optic atrophy is a rare finding.
Limbs 1
Hip dislocation HP:0002827 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hip dislocation (HP:0002827). HP:0002827 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Motor impairments can lead to swallowing difficulty and orthopedic complications, including hip dislocation and scoliosis."
An orthopedic complication of the motor impairment.
Musculoskeletal 3
Hypotonia HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
Hypotonia accompanies nystagmus at onset.
Spasticity HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257), qualified as course progressive. HP:0001257 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Sequelae: Hip dislocation Scoliosis
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Over time the hypotonia typically evolves into spasticity that affects the ability to walk and communicate."
Spasticity develops from the initial hypotonia.
Scoliosis HP:0002650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Scoliosis (HP:0002650). HP:0002650 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Motor impairments can lead to swallowing difficulty and orthopedic complications, including hip dislocation and scoliosis."
An orthopedic complication of the motor impairment.
Nervous System 14
Motor delay HP:0001270 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Delayed acquisition of motor milestones, annotated with Motor delay (HP:0001270). HP:0001270 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
Delayed motor milestones are part of the early picture.
Speech delay Delayed speech and language development HP:0000750 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Speech delay, annotated with Delayed speech and language development (HP:0000750). HP:0000750 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
Speech delay is part of the early picture.
Dysarthria HP:0001260 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysarthria (HP:0001260). HP:0001260 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
Dysarthria is listed among the presenting features.
Gait ataxia HP:0002066 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Gait ataxia (HP:0002066). HP:0002066 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
Gait ataxia is among the childhood cerebellar signs.
Dysmetria HP:0001310 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysmetria (HP:0001310). HP:0001310 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
Dysmetria is among the childhood cerebellar signs.
Intention tremor HP:0002080 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intention tremor (HP:0002080). HP:0002080 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
Intention tremor is among the childhood cerebellar signs.
Head titubation HP:0002599 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Head titubation (HP:0002599). HP:0002599 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
Head titubation is among the childhood cerebellar signs.
Dysdiadochokinesia FREQUENT Dysdiadochokinesis HP:0002075 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dysdiadochokinesia, annotated with Dysdiadochokinesis (HP:0002075). HP:0002075 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
Dysdiadochokinesia is among the cerebellar signs that frequently manifest during childhood.
Mild intellectual disability HP:0001256 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mild intellectual disability (HP:0001256). HP:0001256 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Most individuals have normal cognitive skills or mild intellectual disability"
GeneReviews places cognition in the normal to mildly impaired range for most patients.
Seizures OCCASIONAL Focal-onset seizure HP:0007359 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Frontal lobe epilepsy, annotated with Focal-onset seizure (HP:0007359). HP:0007359 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:23143715 SUPPORT Human Clinical
"The 3 youngest of branch A were bedridden by their first year because of permanent scissoring of their legs and had severe frontal lobe epilepsy. The single patient from branch B was the least affected, being able to walk until 12 years of age and had no epilepsy."
Frontal lobe epilepsy in the severely affected patients of one family and its absence in the mildest patient.
PMID:29276893 SUPPORT Human Clinical
"neurologic complications (spasticity, ataxia, epilepsy, extrapyramidal movement disorders)"
GeneReviews lists epilepsy among the neurological complications to be treated.
Choreoathetosis OCCASIONAL HP:0001266 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Choreoathetosis (HP:0001266). HP:0001266 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Some individuals develop extrapyramidal movement abnormalities (choreoathetosis and dystonia)."
Extrapyramidal signs occur in a subset of patients.
Dystonia OCCASIONAL HP:0001332 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dystonia (HP:0001332). HP:0001332 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Some individuals develop extrapyramidal movement abnormalities (choreoathetosis and dystonia)."
Extrapyramidal signs occur in a subset of patients.
CNS hypomyelination on MRI OBLIGATE HP:0003429 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is CNS hypomyelination (HP:0003429). HP:0003429 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:15192806 SUPPORT Human Clinical
"The hypomyelinating leukodystrophies X-linked Pelizaeus-Merzbacher disease (PMD) and Pelizaeus-Merzbacher-like disease (PMLD) are characterized by nystagmus, progressive spasticity, and ataxia."
Places PMLD among the hypomyelinating leukodystrophies.
PMID:21871435 SUPPORT REVIEW SYNTHESIS Human Clinical
"All patients with PMLD have extensive white matter disease consistent with abnormal myelination on MRI"
Review statement that abnormal myelination on MRI is present in all patients, supporting the obligate frequency.
Demyelinating peripheral neuropathy OCCASIONAL HP:0007108 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mild demyelinating peripheral neuropathy, annotated with Demyelinating peripheral neuropathy (HP:0007108). HP:0007108 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:20513814 SUPPORT Human Clinical
"NCS were normal in all patients with PMD and indicated mild peripheral neuropathy in only 2 of 10 patients with PMLD."
Gives the frequency of peripheral involvement in one series.
🧬

Genetic Associations

1
GJC2
Gene: GJC2 hgnc:17494 gene page HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GJC2 (hgnc:17494). hgnc:17494 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (2 references)
PMID:29276893 SUPPORT Human Clinical
"The diagnosis of PMLD1 is established in a proband with suggestive clinical and neuroimaging findings and identification of biallelic pathogenic variants in GJC2 on molecular genetic testing."
GeneReviews defines the disease by biallelic GJC2 variants.
CGGV:assertion_9bb53a46-83ae-4585-9b6b-c8f1aad1c4ab-2025-03-12T160000.000Z SUPPORT Other
"GJC2 | HGNC:17494 | hypomyelinating leukodystrophy 2 | MONDO:0012125 | AR | Definitive"
ClinGen classifies GJC2 as definitively causing HLD2, autosomal recessive.
Variants (2)
c.-167A>G (promoter)
Homozygous variant in the noncoding exon 1 promoter at a SOX10 binding site. A founder variant in families of Pakistani origin, estimated to account for about 29% of reported GJC2-PMLD patients. It is missed by sequencing that covers only the coding exon.
Show evidence (1 reference)
PMID:21959080 SUPPORT Human Clinical
"This promoter mutation has only recently been reported in GJC2-PMLD but it has been postulated to affect the binding of the transcription factor SOX10 and appears to be a prevalent mutation, accounting for ~29% of reported patients with GJC2-PMLD."
Frequency and proposed mechanism of the promoter variant.
p.M283T
ER-retained missense allele that forms no functional channels and activates the UPR in primary oligodendrocytes; its mouse orthologue (M282T) is the knock-in model.
Show evidence (1 reference)
PMID:21750683 SUPPORT Model Organism
"These results strongly suggest that PMLD1 is caused by the loss of Cx47 channel function that results in impaired panglial coupling in white matter tissue."
Knock-in evidence that this allele acts through loss of panglial coupling.
💊

Medical Actions

3
Supportive Care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Platform: Other
No disease-modifying treatment exists. Care is multidisciplinary and supportive: nutrition and swallowing support, management of spasticity, ataxia, seizures and movement disorders, communication support, and surveillance of hips and spine.
Mechanism Target:
Spasticity — Addresses consequences only; nothing available acts on the coupling defect.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"To date no definite treatment is available; treatment is mainly supportive"
GeneReviews states that management is supportive.
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Platform: Behavioral / lifestyle
Counseling for autosomal recessive inheritance, carrier testing of relatives, and prenatal or preimplantation testing once both familial variants are known.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Once the GJC2 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible."
GeneReviews counseling and reproductive testing options.
Oligodendrocyte-Targeted AAV-GJC2 Gene Therapy (preclinical)
Action: Gene TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Gene Therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. NCIT:C15238
Platform: Gene therapy
Not available to patients. A single intracerebral injection of an AAV vector expressing Cx47 from the myelin basic protein promoter, given on postnatal day 10 to Cx32/Cx47 double-knockout mice, restored oligodendrocyte gap-junction coupling, improved motor performance and prolonged survival.
Mechanism Target:
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling — Replaces Cx47 in oligodendrocytes and re-establishes gap-junction connectivity.
Show evidence (1 reference)
PMID:28100454 SUPPORT Model Organism
"Application of this oligodendrocyte-targeted somatic gene therapy at postnatal Day 10 in groups of double knockout mice, a well characterized model of hypomyelinating leukodystrophy-2, resulted in significant improvement in motor performance and coordination at 1 month of age in treated compared..."
Preclinical efficacy in the double-knockout model.
🔬

Diagnosis

2
Brain MRI and GJC2 Sequencing Including the Promoter
Diagnosis rests on a PMD-like clinical picture with hypomyelination on MRI and biallelic GJC2 variants. Testing should include the noncoding exon 1, where the common promoter variant lies.
Show evidence (2 references)
PMID:29276893 SUPPORT Human Clinical
"The diagnosis of PMLD1 is established in a proband with suggestive clinical and neuroimaging findings and identification of biallelic pathogenic variants in GJC2 on molecular genetic testing."
GeneReviews diagnostic criteria.
PMID:21959080 SUPPORT Human Clinical
"We propose that diagnostic screening of GJC2 should include sequence analysis of the non-coding exon 1, as well as the coding regions to avoid misdiagnosis or diagnostic delay in suspected PMLD."
Why promoter sequencing must be included.
Brainstem Auditory Evoked Potentials to Separate GJC2 from PLP1 Disease
PMD and GJC2 disease are hard to tell apart clinically and on MRI. Brainstem auditory evoked potential waves III-V are absent in PMD but usually recordable in GJC2 disease, which helps choose which gene to test first.
Show evidence (1 reference)
PMID:20513814 SUPPORT Human Clinical
"In brainstem auditory EP, waves III-V were absent in all patients with PMD, but clearly recordable in 11 of 13 investigations in 8 patients with PMLD."
The discriminating neurophysiological result.
📈

Progression

2
Onset
Age: Neonatal to early infancy
Nystagmus is usually the first sign, with hypotonia and delayed motor and speech milestones.
Show evidence (2 references)
PMID:29276893 SUPPORT Human Clinical
"Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
GeneReviews gives the typical age and signs at onset.
PMID:21871435 SUPPORT REVIEW SYNTHESIS Human Clinical
"which is characterized by nystagmus within the first 6 months of life, cerebellar ataxia by 4 years, and spasticity by 6 years of age"
Gives the typical ages at which the cardinal signs appear.
Progression
Age: Childhood onward
Hypotonia evolves into spasticity and cerebellar signs appear during childhood; the course is slow.
Show evidence (1 reference)
PMID:29276893 SUPPORT Human Clinical
"Over time the hypotonia typically evolves into spasticity that affects the ability to walk and communicate."
Describes the evolution from hypotonia to spasticity.
🐁

Animal Models

3
Cx32/Cx47 double-knockout mouse
Species
Mouse
Genotype
Gjb1 null; Gjc2 null
Publication
PMID:12843301
Pathograph links
CNS Hypomyelination recapitulates fidelity: moderate observes: tissue
Limitations: Removes Cx32 as well as Cx47; mice lacking Cx47 alone are nearly normal, so the severity depends on losing a second connexin that human HLD2 patients retain.
Show evidence (1 reference)
PMID:12843301 SUPPORT Model Organism
"animals lacking both connexins die by postnatal week 6 from profound abnormalities in central myelin, characterized by thin or absent myelin sheaths, vacuolation, enlarged periaxonal collars, oligodendrocyte cell death, and axonal loss."
The double knockout produces severe CNS myelin failure.
Cx47 M282T knock-in mouse
Species
Mouse
Genotype
Gjc2 M282T homozygous (orthologue of human p.M283T)
Publication
PMID:21750683
Pathograph links
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling recapitulates fidelity: high observes: cellular Carries a patient-derived allele and loses most glial network coupling.
Show evidence (1 reference)
PMID:21750683 SUPPORT Model Organism
"10-15-day-old homozygous Cx47M282T and Cx47 null mice revealed a more than 80% reduction in the number of cells participating in glial networks after biocytin injections into oligodendrocytes in sections of corpus callosum."
Direct measurement of coupling loss with the patient allele.
CNS Hypomyelination fails to recapitulate fidelity: low observes: tissue
Limitations: Adult knock-in mice show no substantial myelin change unless Cx32 is also removed, whereas patients have lifelong hypomyelination.
Show evidence (1 reference)
PMID:21750683 SUPPORT Model Organism
"Adult mCx47M282T expressing mice did not show substantial myelin alterations"
The single-allele mouse does not reproduce the human myelin lesion.
Toy Poodle GJC2 frameshift hypomyelinating leukodystrophy
Species
Dog
Genotype
GJC2 c.920_933del homozygous
Publication
PMID:42543680
Pathograph links
CNS Hypomyelination recapitulates fidelity: moderate observes: tissue Naturally occurring canine GJC2 disease with white matter vacuolation and demyelination.
Limitations: Six affected dogs, all euthanized young; no functional or longitudinal data yet.
Show evidence (1 reference)
PMID:42543680 SUPPORT Model Organism
"Subsequent histopathological examination revealed vacuolar changes and demyelination in the cerebral and cerebellar white matter, leading to a diagnosis of HLD."
Neuropathology in the spontaneous canine model.
{ }

Source YAML

click to show 
name: Hypomyelinating Leukodystrophy 2
creation_date: "2026-10-16T00:00:00Z"
category: Genetic
synonyms:
- Pelizaeus-Merzbacher-like disease 1
- PMLD1
- HLD2
- GJC2 leukodystrophy
- Pelizaeus-Merzbacher-like disease due to GJC2 mutation
parents:
- Leukodystrophy
disease_term:
  preferred_term: hypomyelinating leukodystrophy 2
  term:
    id: MONDO:0012125
    label: leukodystrophy, hypomyelinating, 2
description: >-
  Autosomal recessive hypomyelinating leukodystrophy caused by biallelic GJC2
  variants. GJC2 encodes connexin-47 (Cx47), the gap-junction protein that
  couples oligodendrocytes to astrocytes (through Cx47/Cx43 channels) and to
  each other. The disease is the autosomal recessive phenocopy of
  Pelizaeus-Merzbacher disease: nystagmus beginning in the neonatal or
  early-infantile period, hypotonia that evolves into spasticity, cerebellar
  signs in childhood, and diffuse CNS hypomyelination on MRI, usually with
  normal cognition or mild intellectual disability and a slowly progressive
  course.

  Two mechanisms are documented for the same protein. Most coding alleles
  abolish channel function, and several (p.P87S, p.Y269D, p.M283T) are also
  retained in the endoplasmic reticulum, where in primary oligodendrocytes they
  switch on the unfolded protein response and apoptotic pathways. A recurrent
  promoter variant (c.-167A>G) instead removes a SOX10 binding site and lowers
  GJC2 transcription. The milder allelic disorder, spastic paraplegia 44, is
  curated separately.
notes: >-
  The gene is written GJA12 (connexin 46.6) in the founding 2004 report and in
  other literature before the HGNC renaming. A large fraction of PMD-like
  hypomyelination with a normal PLP1 locus is not explained by GJC2 either;
  "Pelizaeus-Merzbacher-like disease" in the older literature is a phenotype
  label that also covers other genes (for example AIMP1), and only the GJC2
  form is this entry.
inheritance:
- name: Autosomal recessive
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PMLD1 is inherited in an autosomal recessive manner."
    explanation: GeneReviews states the mode of inheritance.
progression:
- phase: Onset
  age_range: Neonatal to early infancy
  notes: >-
    Nystagmus is usually the first sign, with hypotonia and delayed motor and
    speech milestones.
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
    explanation: GeneReviews gives the typical age and signs at onset.
  - reference: PMID:21871435
    reference_title: "Gap junctions in inherited human disorders of the central nervous system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "which is characterized by nystagmus within the first 6 months of life, cerebellar ataxia by 4 years, and spasticity by 6 years of age"
    explanation: Gives the typical ages at which the cardinal signs appear.
- phase: Progression
  age_range: Childhood onward
  notes: >-
    Hypotonia evolves into spasticity and cerebellar signs appear during
    childhood; the course is slow.
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Over time the hypotonia typically evolves into spasticity that affects the ability to walk and communicate."
    explanation: Describes the evolution from hypotonia to spasticity.
pathophysiology:
- name: Biallelic GJC2 Loss of Function
  description: >-
    Biallelic GJC2 variants remove connexin-47 channel function from
    oligodendrocytes. Missense, nonsense and frameshift alleles were found in
    the founding families. Expressed in cell lines, the missense alleles P87S,
    Y269D and M283T form no functional channels. The recurrent promoter variant
    c.-167A>G acts upstream of the protein, abolishing a SOX10 binding site and
    lowering promoter activity.
  conforms_to: "cns_myelin_failure#Oligodendrocyte-Lineage or Myelin-Membrane Insult"
  biological_scale: MOLECULAR
  genes:
  - preferred_term: GJC2
    term:
      id: hgnc:17494
      label: GJC2
  genetic_context:
    functional_impact_category: LOSS_OF_FUNCTION
    variant_origin: GERMLINE
  molecular_functions:
  - preferred_term: connexin-47 gap junction channel activity
    modifier: LOSS_OF_FUNCTION
    term:
      id: GO:0005243
      label: gap junction channel activity
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  downstream:
  - target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
    causal_link_type: DIRECT
  - target: Connexin-47 ER Retention and Unfolded Protein Response
    causal_link_type: DIRECT
    description: >-
      Applies to the ER-retained missense alleles, not to the promoter variant
      or to truncating alleles.
  evidence:
  - reference: PMID:15192806
    reference_title: "Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In three of six families with PMLD, we detected five different GJA12 mutations, including missense, nonsense, and frameshift mutations."
    explanation: The founding gene discovery, in human families.
  - reference: PMID:17344063
    reference_title: "Loss-of-function GJA12/Connexin47 mutations cause Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Dual whole-cell patch clamping of transfected Neuro2A cells demonstrated that none of the mutants formed functional channels, in contrast to wild type Cx47."
    explanation: Shows directly that three patient missense alleles are channel-dead.
  - reference: PMID:20695017
    reference_title: "Disrupted SOX10 regulation of GJC2 transcription causes Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functionally, this mutation completely abolished the SOX10 binding and attenuated GJC2 promoter activity."
    explanation: Establishes the transcriptional route to loss of function for the promoter variant.
- name: Connexin-47 ER Retention and Unfolded Protein Response
  description: >-
    Several PMLD1 missense proteins are retained in the endoplasmic reticulum
    instead of reaching the plasma membrane. In primary oligodendrocytes, three
    such mutants activate the unfolded protein response and apoptotic pathways,
    a toxic gain of function on top of channel loss. The milder SPG44 allele
    p.I33M traffics normally and activates neither, which is one measured
    difference between the severe and mild ends of the GJC2 spectrum.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: unfolded protein response
    modifier: INCREASED
    term:
      id: GO:0030968
      label: endoplasmic reticulum unfolded protein response
  downstream:
  - target: Oligodendrocyte Apoptosis
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:35276347
    reference_title: "Activation of the unfolded protein response by Connexin47 mutations associated with Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Here we show that when expressed in primary OLs, three PMLD1 associated mutants (p.P87S, p.Y269D and p.M283T) show ER retention of Cx47 and evidence of activation of the cellular stress (unfolded protein response, UPR) and apoptotic pathways."
    explanation: Primary-oligodendrocyte evidence for ER retention and UPR activation.
  - reference: PMID:20442743
    reference_title: "Pelizaeus-Merzbacher-like disease is caused not only by a loss of connexin47 function but also by a hemichannel dysfunction."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The mutants T265A and A98G_V99insT were retained in the ER, T398I formed gap junctional plaques at the plasma membrane, and G149S showed both, structures at the plasma membrane and ER localization."
    explanation: >-
      ER retention is allele-specific; one mutant reaches the membrane, which
      is why this branch does not cover every allele.
- name: Oligodendrocyte Apoptosis
  description: >-
    Death of oligodendrocytes downstream of ER stress in cells carrying
    ER-retained mutants, and in the Cx32/Cx47 double-knockout mouse, where
    restoring Cx47 to oligodendrocytes reduces it.
  conforms_to: "cns_myelin_failure#Oligodendrocyte Differentiation Arrest and Death"
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  downstream:
  - target: CNS Hypomyelination
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:35276347
    reference_title: "Activation of the unfolded protein response by Connexin47 mutations associated with Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These studies provide new insight into a potential element of toxic gain of function underlying the mechanism of PMLD1"
    explanation: The authors frame the apoptotic activation as a candidate toxic gain-of-function mechanism, with their hedge kept.
  - reference: PMID:12843301
    reference_title: "Connexins are critical for normal myelination in the CNS."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "animals lacking both connexins die by postnatal week 6 from profound abnormalities in central myelin, characterized by thin or absent myelin sheaths, vacuolation, enlarged periaxonal collars, oligodendrocyte cell death, and axonal loss."
    explanation: >-
      Oligodendrocyte death in the double-knockout mouse. INDIRECT because the
      genotype removes Cx32 as well as Cx47.
- name: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
  description: >-
    Oligodendrocytes couple to astrocytes through heterotypic Cx47/Cx43 and
    Cx32/Cx30 channels. PMLD1 mutants fail to form functional channels with
    astrocytic Cx43, and a knock-in mouse carrying the orthologue of human
    M283T loses most glial network coupling in the corpus callosum, as Cx47-null
    mice do. Loss of this panglial network, rather than of Cx47 protein as
    such, is the proposed core of the disease.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  molecular_functions:
  - preferred_term: heterotypic Cx47/Cx43 gap junction channel activity
    modifier: DECREASED
    term:
      id: GO:0005243
      label: gap junction channel activity
  cellular_components:
  - preferred_term: oligodendrocyte-astrocyte gap junction
    term:
      id: GO:0005921
      label: gap junction
  downstream:
  - target: Impaired Potassium Spatial Buffering
    causal_link_type: DIRECT
  - target: CNS Hypomyelination
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Microglial Activation and White Matter Inflammation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:18094232
    reference_title: "Two distinct heterotypic channels mediate gap junction coupling between astrocyte and oligodendrocyte connexins."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Finally, Cx47 mutants that cause Pelizaeus-Merzbacher-like disease do not efficiently form functional channels with Cx43, indicating that disrupted Cx47/Cx43 channels cause this disease."
    explanation: Identifies the heterotypic oligodendrocyte-astrocyte channel as the one the patient mutants lose.
  - reference: PMID:21750683
    reference_title: "Pathologic and phenotypic alterations in a mouse expressing a connexin47 missense mutation that causes Pelizaeus-Merzbacher-like disease in humans."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "10-15-day-old homozygous Cx47M282T and Cx47 null mice revealed a more than 80% reduction in the number of cells participating in glial networks after biocytin injections into oligodendrocytes in sections of corpus callosum."
    explanation: In vivo loss of glial network coupling with a patient-derived allele.
- name: Impaired Potassium Spatial Buffering
  description: >-
    Oligodendrocyte connexins take part, with the astrocytic K+ channel Kir4.1,
    in clearing the K+ released by active axons. Without them, myelin develops
    vacuoles whose size and number track axonal activity. Shown in mice lacking
    both oligodendrocyte connexins; how much this contributes in human HLD2 is
    not established.
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: potassium ion homeostasis
    modifier: DECREASED
    term:
      id: GO:0055075
      label: potassium ion homeostasis
  downstream:
  - target: CNS Hypomyelination
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Activity-dependent myelin vacuolation contributes to the unstable sheath.
  evidence:
  - reference: PMID:17065440
    reference_title: "Genetic and physiological evidence that oligodendrocyte gap junctions contribute to spatial buffering of potassium released during neuronal activity."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "The size and number of myelin vacuoles was dramatically increased when axonal activity was increased, by either a natural stimulus (eye opening) or pharmacological treatment."
    explanation: >-
      Activity dependence of the myelin lesion in Cx32/Cx47 double-knockout
      mice. INDIRECT because the genotype also removes Cx32.
  - reference: PMID:17065440
    reference_title: "Genetic and physiological evidence that oligodendrocyte gap junctions contribute to spatial buffering of potassium released during neuronal activity."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Together, these results implicate oligodendrocytes and their connexins as having critical roles in the buffering of K+ released during neuronal activity."
    explanation: The authors' conclusion tying the connexins to K+ buffering.
- name: Microglial Activation and White Matter Inflammation
  description: >-
    In mice lacking both oligodendrocyte connexins, the affected cerebellum
    shows activated microglia and astrocytes and infiltrating T and B cells,
    alongside reduced expression of myelin-lipid synthesis genes. Human
    neuropathology to confirm this arm is not available.
  conforms_to: "cns_myelin_failure#Microglial Injury and Reactive Gliosis"
  biological_scale: TISSUE
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  downstream:
  - target: CNS Hypomyelination
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:26051537
    reference_title: "Activated immune response in an inherited leukodystrophy disease caused by the loss of oligodendrocyte gap junctions."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In accord, immunostaining showed T- and B-cells in the cerebella of mutant mice as well as activated microglia and astrocytes."
    explanation: Immune and glial activation in the double-knockout model.
- name: CNS Hypomyelination
  description: >-
    The tissue-level lesion: CNS myelin is deficient from the start, seen on
    MRI as diffuse hypomyelination. In mice the lesion appears as vacuolated
    myelinated fibres with Cx47 loss alone and as thin or absent sheaths when
    Cx32 is also removed.
  conforms_to: "cns_myelin_failure#Deficient or Unstable CNS Myelin Sheath"
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: central nervous system myelination
    modifier: DECREASED
    term:
      id: GO:0022010
      label: central nervous system myelination
  downstream:
  - target: CNS hypomyelination on MRI
    causal_link_type: DIRECT
  - target: Nystagmus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Motor delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Speech delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dysarthria
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Spasticity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Gait ataxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dysmetria
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Intention tremor
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Head titubation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dysdiadochokinesia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Mild intellectual disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Choreoathetosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dystonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Optic atrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hearing loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Dysphagia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: GeneReviews attributes swallowing difficulty to the motor impairment.
  evidence:
  - reference: PMID:15192806
    reference_title: "Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this study, we demonstrate that GJA12 plays a key role in central myelination and is involved in peripheral myelination in humans."
    explanation: The founding authors' conclusion from the human families.
  - reference: PMID:12805295
    reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Electron microscopic analysis of CNS white matter in Cx47-deficient mice revealed a conspicuous vacuolation of nerve fibers, particularly at the site of the optic nerve where axons are first contacted by oligodendrocytes and myelination starts."
    explanation: Myelin pathology attributable to Cx47 loss alone.
- name: Peripheral Nerve Myelin Involvement
  description: >-
    Unlike in mice, GJC2 is transcribed in human peripheral nerve, and some
    patients have slowed nerve conduction consistent with a mild demyelinating
    neuropathy. It is a minority finding (2 of 10 patients in one
    neurophysiology series).
  biological_scale: TISSUE
  downstream:
  - target: Demyelinating peripheral neuropathy
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:15192806
    reference_title: "Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These results are in accordance with the electrophysiological finding of reduced motor and sensory nerve conduction velocities in patients with PMLD, which argues for a demyelinating neuropathy."
    explanation: Human peripheral nerve conduction findings.
phenotypes:
- name: Nystagmus
  category: Neurological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
    explanation: Nystagmus is the typical presenting sign.
- name: Hypotonia
  category: Neurological
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
    explanation: Hypotonia accompanies nystagmus at onset.
- name: Motor delay
  category: Neurological
  phenotype_term:
    preferred_term: Delayed acquisition of motor milestones
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
    explanation: Delayed motor milestones are part of the early picture.
- name: Speech delay
  category: Neurological
  phenotype_term:
    preferred_term: Speech delay
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
    explanation: Speech delay is part of the early picture.
- name: Dysarthria
  category: Neurological
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pelizaeus-Merzbacher-like disease 1 (PMLD1) is a slowly progressive leukodystrophy that typically presents during the neonatal or early-infantile period with nystagmus, commonly associated with hypotonia, delayed acquisition of motor milestones, speech delay, and dysarthria."
    explanation: Dysarthria is listed among the presenting features.
- name: Spasticity
  category: Neurological
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
    clinical_course: PROGRESSIVE
  sequelae:
  - target: Hip dislocation
  - target: Scoliosis
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Over time the hypotonia typically evolves into spasticity that affects the ability to walk and communicate."
    explanation: Spasticity develops from the initial hypotonia.
- name: Gait ataxia
  category: Neurological
  phenotype_term:
    preferred_term: Gait ataxia
    term:
      id: HP:0002066
      label: Gait ataxia
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
    explanation: Gait ataxia is among the childhood cerebellar signs.
- name: Dysmetria
  category: Neurological
  phenotype_term:
    preferred_term: Dysmetria
    term:
      id: HP:0001310
      label: Dysmetria
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
    explanation: Dysmetria is among the childhood cerebellar signs.
- name: Intention tremor
  category: Neurological
  phenotype_term:
    preferred_term: Intention tremor
    term:
      id: HP:0002080
      label: Intention tremor
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
    explanation: Intention tremor is among the childhood cerebellar signs.
- name: Head titubation
  category: Neurological
  phenotype_term:
    preferred_term: Head titubation
    term:
      id: HP:0002599
      label: Head titubation
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
    explanation: Head titubation is among the childhood cerebellar signs.
- name: Dysdiadochokinesia
  category: Neurological
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Dysdiadochokinesia
    term:
      id: HP:0002075
      label: Dysdiadochokinesis
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cerebellar signs (gait ataxia, dysmetria, intention tremor, head titubation, and dysdiadochokinesia) frequently manifest during childhood."
    explanation: Dysdiadochokinesia is among the cerebellar signs that frequently manifest during childhood.
- name: Mild intellectual disability
  category: Neurodevelopmental
  description: >-
    Cognition is normal or mildly impaired in most patients, and is hard to
    assess against the severity of the motor impairment.
  phenotype_term:
    preferred_term: Mild intellectual disability
    term:
      id: HP:0001256
      label: Mild intellectual disability
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most individuals have normal cognitive skills or mild intellectual disability"
    explanation: GeneReviews places cognition in the normal to mildly impaired range for most patients.
- name: Seizures
  category: Neurological
  frequency: OCCASIONAL
  description: >-
    Epilepsy is listed among the neurological complications that need
    treatment, and is reported at the severe end of the spectrum; in one large
    consanguineous family the most severely affected branch had frontal lobe
    epilepsy while the mildest patient had none.
  phenotype_term:
    preferred_term: Frontal lobe epilepsy
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: PMID:23143715
    reference_title: "Pelizaeus-Merzbacher-Like Disease in a Family With Variable Phenotype and a Novel Splicing GJC2 Mutation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The 3 youngest of branch A were bedridden by their first year because of permanent scissoring of their legs and had severe frontal lobe epilepsy. The single patient from branch B was the least affected, being able to walk until 12 years of age and had no epilepsy."
    explanation: Frontal lobe epilepsy in the severely affected patients of one family and its absence in the mildest patient.
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "neurologic complications (spasticity, ataxia, epilepsy, extrapyramidal movement disorders)"
    explanation: GeneReviews lists epilepsy among the neurological complications to be treated.
- name: Choreoathetosis
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Choreoathetosis
    term:
      id: HP:0001266
      label: Choreoathetosis
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some individuals develop extrapyramidal movement abnormalities (choreoathetosis and dystonia)."
    explanation: Extrapyramidal signs occur in a subset of patients.
- name: Dystonia
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some individuals develop extrapyramidal movement abnormalities (choreoathetosis and dystonia)."
    explanation: Extrapyramidal signs occur in a subset of patients.
- name: Optic atrophy
  category: Neurological
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Optic atrophy
    term:
      id: HP:0000648
      label: Optic atrophy
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing loss and optic atrophy are observed in rare cases."
    explanation: Optic atrophy is a rare finding.
- name: Hearing loss
  category: Neurological
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Hearing loss
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing loss and optic atrophy are observed in rare cases."
    explanation: Hearing loss is a rare finding.
- name: Dysphagia
  category: Neurological
  phenotype_term:
    preferred_term: Swallowing difficulty
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Motor impairments can lead to swallowing difficulty and orthopedic complications, including hip dislocation and scoliosis."
    explanation: Swallowing difficulty is a consequence of the motor impairment.
- name: Hip dislocation
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Hip dislocation
    term:
      id: HP:0002827
      label: Hip dislocation
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Motor impairments can lead to swallowing difficulty and orthopedic complications, including hip dislocation and scoliosis."
    explanation: An orthopedic complication of the motor impairment.
- name: Scoliosis
  category: Musculoskeletal
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Motor impairments can lead to swallowing difficulty and orthopedic complications, including hip dislocation and scoliosis."
    explanation: An orthopedic complication of the motor impairment.
- name: CNS hypomyelination on MRI
  category: Neurological
  frequency: OBLIGATE
  phenotype_term:
    preferred_term: CNS hypomyelination
    term:
      id: HP:0003429
      label: CNS hypomyelination
  evidence:
  - reference: PMID:15192806
    reference_title: "Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The hypomyelinating leukodystrophies X-linked Pelizaeus-Merzbacher disease (PMD) and Pelizaeus-Merzbacher-like disease (PMLD) are characterized by nystagmus, progressive spasticity, and ataxia."
    explanation: Places PMLD among the hypomyelinating leukodystrophies.
  - reference: PMID:21871435
    reference_title: "Gap junctions in inherited human disorders of the central nervous system."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "All patients with PMLD have extensive white matter disease consistent with abnormal myelination on MRI"
    explanation: Review statement that abnormal myelination on MRI is present in all patients, supporting the obligate frequency.
- name: Demyelinating peripheral neuropathy
  category: Neurological
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Mild demyelinating peripheral neuropathy
    term:
      id: HP:0007108
      label: Demyelinating peripheral neuropathy
  evidence:
  - reference: PMID:20513814
    reference_title: "Clinical neurophysiology in GJA12-related hypomyelination vs Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NCS were normal in all patients with PMD and indicated mild peripheral neuropathy in only 2 of 10 patients with PMLD."
    explanation: Gives the frequency of peripheral involvement in one series.
genetic:
- name: GJC2
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: GJC2
    term:
      id: hgnc:17494
      label: GJC2
  gene_disease_validity:
  - validity_classification: DEFINITIVE
    classified_by: CLINGEN
    external_id: CGGV:assertion_9bb53a46-83ae-4585-9b6b-c8f1aad1c4ab-2025-03-12T160000.000Z
    evidence:
    - reference: CGGV:assertion_9bb53a46-83ae-4585-9b6b-c8f1aad1c4ab-2025-03-12T160000.000Z
      reference_title: "GJC2 / hypomyelinating leukodystrophy 2 (Definitive)"
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "GJC2 | HGNC:17494 | hypomyelinating leukodystrophy 2 | MONDO:0012125 | AR | Definitive"
      explanation: ClinGen classifies GJC2 as definitively causing HLD2, autosomal recessive.
  notes: >-
    Encodes connexin-47. Written GJA12 in older literature. Coding variants of
    all classes and a recurrent promoter variant are reported. Biallelic GJC2
    variants also cause spastic paraplegia 44, and heterozygous variants are
    reported in hereditary lymphedema; neither is part of this entry.
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of PMLD1 is established in a proband with suggestive clinical and neuroimaging findings and identification of biallelic pathogenic variants in GJC2 on molecular genetic testing."
    explanation: GeneReviews defines the disease by biallelic GJC2 variants.
  - reference: CGGV:assertion_9bb53a46-83ae-4585-9b6b-c8f1aad1c4ab-2025-03-12T160000.000Z
    reference_title: "GJC2 / hypomyelinating leukodystrophy 2 (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "GJC2 | HGNC:17494 | hypomyelinating leukodystrophy 2 | MONDO:0012125 | AR | Definitive"
    explanation: ClinGen classifies GJC2 as definitively causing HLD2, autosomal recessive.
  variants:
  - name: c.-167A>G (promoter)
    description: >-
      Homozygous variant in the noncoding exon 1 promoter at a SOX10 binding
      site. A founder variant in families of Pakistani origin, estimated to
      account for about 29% of reported GJC2-PMLD patients. It is missed by
      sequencing that covers only the coding exon.
    evidence:
    - reference: PMID:21959080
      reference_title: "Promoter mutation is a common variant in GJC2-associated Pelizaeus-Merzbacher-like disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "This promoter mutation has only recently been reported in GJC2-PMLD but it has been postulated to affect the binding of the transcription factor SOX10 and appears to be a prevalent mutation, accounting for ~29% of reported patients with GJC2-PMLD."
      explanation: Frequency and proposed mechanism of the promoter variant.
  - name: p.M283T
    description: >-
      ER-retained missense allele that forms no functional channels and
      activates the UPR in primary oligodendrocytes; its mouse orthologue
      (M282T) is the knock-in model.
    evidence:
    - reference: PMID:21750683
      reference_title: "Pathologic and phenotypic alterations in a mouse expressing a connexin47 missense mutation that causes Pelizaeus-Merzbacher-like disease in humans."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "These results strongly suggest that PMLD1 is caused by the loss of Cx47 channel function that results in impaired panglial coupling in white matter tissue."
      explanation: Knock-in evidence that this allele acts through loss of panglial coupling.
diagnosis:
- name: Brain MRI and GJC2 Sequencing Including the Promoter
  description: >-
    Diagnosis rests on a PMD-like clinical picture with hypomyelination on MRI
    and biallelic GJC2 variants. Testing should include the noncoding exon 1,
    where the common promoter variant lies.
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The diagnosis of PMLD1 is established in a proband with suggestive clinical and neuroimaging findings and identification of biallelic pathogenic variants in GJC2 on molecular genetic testing."
    explanation: GeneReviews diagnostic criteria.
  - reference: PMID:21959080
    reference_title: "Promoter mutation is a common variant in GJC2-associated Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We propose that diagnostic screening of GJC2 should include sequence analysis of the non-coding exon 1, as well as the coding regions to avoid misdiagnosis or diagnostic delay in suspected PMLD."
    explanation: Why promoter sequencing must be included.
- name: Brainstem Auditory Evoked Potentials to Separate GJC2 from PLP1 Disease
  description: >-
    PMD and GJC2 disease are hard to tell apart clinically and on MRI.
    Brainstem auditory evoked potential waves III-V are absent in PMD but
    usually recordable in GJC2 disease, which helps choose which gene to test
    first.
  evidence:
  - reference: PMID:20513814
    reference_title: "Clinical neurophysiology in GJA12-related hypomyelination vs Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In brainstem auditory EP, waves III-V were absent in all patients with PMD, but clearly recordable in 11 of 13 investigations in 8 patients with PMLD."
    explanation: The discriminating neurophysiological result.
treatments:
- name: Supportive Care
  description: >-
    No disease-modifying treatment exists. Care is multidisciplinary and
    supportive: nutrition and swallowing support, management of spasticity,
    ataxia, seizures and movement disorders, communication support, and
    surveillance of hips and spine.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Spasticity
    description: Addresses consequences only; nothing available acts on the coupling defect.
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date no definite treatment is available; treatment is mainly supportive"
    explanation: GeneReviews states that management is supportive.
- name: Genetic Counseling
  description: >-
    Counseling for autosomal recessive inheritance, carrier testing of
    relatives, and prenatal or preimplantation testing once both familial
    variants are known.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:29276893
    reference_title: "Pelizaeus-Merzbacher-Like Disease 1."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once the GJC2 pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible."
    explanation: GeneReviews counseling and reproductive testing options.
- name: Oligodendrocyte-Targeted AAV-GJC2 Gene Therapy (preclinical)
  description: >-
    Not available to patients. A single intracerebral injection of an AAV
    vector expressing Cx47 from the myelin basic protein promoter, given on
    postnatal day 10 to Cx32/Cx47 double-knockout mice, restored
    oligodendrocyte gap-junction coupling, improved motor performance and
    prolonged survival.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
    description: Replaces Cx47 in oligodendrocytes and re-establishes gap-junction connectivity.
  evidence:
  - reference: PMID:28100454
    reference_title: "Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Application of this oligodendrocyte-targeted somatic gene therapy at postnatal Day 10 in groups of double knockout mice, a well characterized model of hypomyelinating leukodystrophy-2, resulted in significant improvement in motor performance and coordination at 1 month of age in treated compared to mock-treated mice, as well as prolonged survival."
    explanation: Preclinical efficacy in the double-knockout model.
animal_models:
- name: Cx32/Cx47 double-knockout mouse
  species: Mouse
  genotype: Gjb1 null; Gjc2 null
  publication: PMID:12843301
  modeled_mechanisms:
  - target: CNS Hypomyelination
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    limitations: >-
      Removes Cx32 as well as Cx47; mice lacking Cx47 alone are nearly
      normal, so the severity depends on losing a second connexin that human
      HLD2 patients retain.
    evidence:
    - reference: PMID:12843301
      reference_title: "Connexins are critical for normal myelination in the CNS."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "animals lacking both connexins die by postnatal week 6 from profound abnormalities in central myelin, characterized by thin or absent myelin sheaths, vacuolation, enlarged periaxonal collars, oligodendrocyte cell death, and axonal loss."
      explanation: The double knockout produces severe CNS myelin failure.
- name: Cx47 M282T knock-in mouse
  species: Mouse
  genotype: Gjc2 M282T homozygous (orthologue of human p.M283T)
  publication: PMID:21750683
  modeled_mechanisms:
  - target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
    relationship: RECAPITULATES
    fidelity: HIGH
    model_scale: CELLULAR
    description: Carries a patient-derived allele and loses most glial network coupling.
    evidence:
    - reference: PMID:21750683
      reference_title: "Pathologic and phenotypic alterations in a mouse expressing a connexin47 missense mutation that causes Pelizaeus-Merzbacher-like disease in humans."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "10-15-day-old homozygous Cx47M282T and Cx47 null mice revealed a more than 80% reduction in the number of cells participating in glial networks after biocytin injections into oligodendrocytes in sections of corpus callosum."
      explanation: Direct measurement of coupling loss with the patient allele.
  - target: CNS Hypomyelination
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    model_scale: TISSUE
    limitations: >-
      Adult knock-in mice show no substantial myelin change unless Cx32 is
      also removed, whereas patients have lifelong hypomyelination.
    evidence:
    - reference: PMID:21750683
      reference_title: "Pathologic and phenotypic alterations in a mouse expressing a connexin47 missense mutation that causes Pelizaeus-Merzbacher-like disease in humans."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Adult mCx47M282T expressing mice did not show substantial myelin alterations"
      explanation: The single-allele mouse does not reproduce the human myelin lesion.
- name: Toy Poodle GJC2 frameshift hypomyelinating leukodystrophy
  species: Dog
  genotype: GJC2 c.920_933del homozygous
  publication: PMID:42543680
  modeled_mechanisms:
  - target: CNS Hypomyelination
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: Naturally occurring canine GJC2 disease with white matter vacuolation and demyelination.
    limitations: >-
      Six affected dogs, all euthanized young; no functional or longitudinal
      data yet.
    evidence:
    - reference: PMID:42543680
      reference_title: "Gap junction protein gamma 2 (GJC2) gene frameshift deletion in Toy Poodles with hypomyelinating leukodystrophy resembling human Pelizaeus-Merzbacher-like disease 1."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Subsequent histopathological examination revealed vacuolar changes and demyelination in the cerebral and cerebellar white matter, leading to a diagnosis of HLD."
      explanation: Neuropathology in the spontaneous canine model.
references:
- reference: PMID:29276893
  title: "Pelizaeus-Merzbacher-Like Disease 1."
  tags:
  - GeneReviews
📚

References & Deep Research

References

1
PMID:29276893
Pelizaeus-Merzbacher-Like Disease 1.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Reconcile HLD2 with OpenScientist deep research · 2026-10-16T01:19:18Z · View source

Reconciled the entry with research/Hypomyelinating_Leukodystrophy_2-deep-research-openscientist.md (34/34 references resolved, 23 judged on-topic). Two leads were taken after fetching and quoting the sources directly: an Impaired Potassium Spatial Buffering node (PMID:17065440, Cx32/Cx47 double-knockout mice, marked INDIRECT) between panglial uncoupling and hypomyelination, and the onset timeline of nystagmus by 6 months, ataxia by 4 years and spasticity by 6 years (PMID:21871435, a review). The rest of the report's mechanism, phenotype, diagnosis and model content was already covered by the entry. Validated: validate, validate-terms, count-verified-snippets 53/53, check-causal-targets, check-entity-refs.

Create: Hypomyelinating Leukodystrophy 2 (PMLD1, GJC2) · 2026-10-16T00:47:22Z · View source

New entry for HLD2 (MONDO:0012125). Deep research was attempted with falcon (503 authentication failure, also with --fallback) and openai (401, invalid key); an openscientist run was still in progress at the time of this commit, so the entry was written from primary literature fetched with just fetch-reference: the GeneReviews PMLD1 chapter (PMID:29276893), the founding GJA12 report (PMID:15192806), channel, UPR and promoter studies, the Cx47/Cx32 mouse models and the AAV gene-therapy study. Six fetched references that ended up uncited were removed. ClinGen Definitive AR (CGGV assertion 9bb53a46) recorded as gene_disease_validity. Pathophysiology conforms to cns_myelin_failure at four nodes. Validated with just validate, validate-terms and count-verified-snippets (50/50); all 19 phenotypes are causally connected.

OpenScientist ▸
1. Disease Information
openscientist-autonomous 34 citations 2026-10-16T00:55:19.505832

1. Disease Information

HLD2/PMLD1 is an inherited genetic disease of the central nervous system characterized by insufficient deposition of myelin (hypomyelination) during development. It belongs to the broader family of hypomyelinating leukodystrophies and is the autosomal recessive counterpart of X‑linked Pelizaeus‑Merzbacher disease. A review describes it directly as an "inherited genetic disease of the central nervous system caused by recessive mutations in the gap junction protein gamma 2 (GJC2/GJA12)" (PMID: 35794704).

Key identifiers:

Resource Identifier
MONDO MONDO:0012125
OMIM #608804 (PMLD1 / HLD2)
Orphanet ORPHA:280229 (hypomyelinating leukodystrophy, GJC2‑related subset)
Gene (HGNC) GJC2 (prev. GJA12); protein connexin 47 (Cx47 / Cx46.6)
MeSH Pelizaeus‑Merzbacher disease (closest term)

Synonyms / alternative names: Pelizaeus‑Merzbacher‑like disease 1; PMLD1; PMLD; hypomyelinating leukodystrophy type 2; GJC2‑related/GJA12‑related hypomyelinating leukodystrophy; connexin‑47 deficiency.

Information source type: Disease‑level knowledge is derived predominantly from aggregated resources (OMIM, Orphanet) and from individual patient/family case reports and small cohort studies, rather than from large EHR‑based populations. One large‑scale population screening + EHR study (210,983 individuals across 19 leukodystrophy genes) contributes penetrance data (PMID: 42465930).

2. Etiology

Primary cause — genetic. HLD2 is caused by biallelic (autosomal recessive) loss‑of‑function mutations in GJC2/GJA12 encoding connexin 47. The causal demonstration came from identification of homozygous truncating mutations tightly segregating with disease in large consanguineous families: "The identification of homozygous mutations predicting the synthesis of aberrant and truncated polypeptides, and their tight segregation with the disease in very large families, clearly demonstrate that the loss of Cx47 function is the cause of the disease" (PMID: 16707726).

Genetic risk factors. The disease is monogenic; the dominant risk factor is carriage of two pathogenic GJC2 alleles. Consanguinity is a major contributor, as most reported families are consanguineous (Italian, Pakistani, Saudi, Iranian, Turkish). A founder promoter mutation (c.-167A>G) that disrupts SOX10 transcription‑factor binding is a prevalent allele in Pakistani‑origin families, accounting for ~29% of reported GJC2‑PMLD patients (PMID: 21959080). No validated common susceptibility loci or modifier genes have been established, though allele identity itself is the chief modifier of severity (see §4, §6).

Environmental risk factors. None established. HLD2 is a Mendelian disorder with no demonstrated toxic, infectious, occupational, or lifestyle etiology. Sex is not a risk factor (autosomal, affects both sexes).

Protective factors. No genetic or environmental protective factors are documented. On the milder end of the allelic spectrum, specific hypomorphic missense alleles (e.g., p.I33M) produce markedly attenuated disease (SPG44), but these are allelic variants rather than protective modifiers (PMID: 19056803).

Gene–environment interactions. Not established. Experimental evidence indicates activity‑dependent myelin pathology (K⁺ released during neuronal activity drives vacuolation when buffering fails), which is a gene–physiology rather than gene–environment interaction (PMID: 17065440).

3. Phenotypes

HLD2 is a neurological disorder; its phenotypes are chiefly clinical signs and neurodevelopmental manifestations. The cardinal temporal sequence is well defined: "characterized by nystagmus within the first 6 months of life, cerebellar ataxia by 4 years, and spasticity by 6 years of age. MRI imaging shows abnormal myelination" (PMID: 21871435). Broader cohort features include "psychomotor developmental delay, spasticity, nystagmus, impairment of cognitive skills, sensorineural hearing loss, and different ophthalmological disabilities" (PMID: 31270756).

Phenotype Type HPO term Onset Progression Frequency
Nystagmus Clinical sign (ocular) HP:0000639 First 6 months Early, often improves Very frequent (cardinal)
Cerebellar ataxia Clinical sign HP:0001251 By ~4 years Progressive Frequent
Spasticity Clinical sign HP:0001257 By ~6 years Progressive Frequent (cardinal)
Psychomotor developmental delay Sign HP:0001263 Infancy Static/progressive Frequent
Cognitive impairment Sign HP:0001249 Childhood Variable Common
Sensorineural hearing loss Lab/clinical HP:0000407 Childhood Variable Subset
Ophthalmologic disability Sign HP:0000504 Childhood Variable Subset
Seizures / frontal lobe epilepsy Sign HP:0001250 Severe infantile forms — Subset (severe end)
Spastic paraparesis (late‑onset / SPG44) Sign HP:0002061 Adulthood (mild allele) Slowly progressive Mild allelic end
Peripheral demyelinating neuropathy (reduced NCV) Lab HP:0000762 Variable — Subset

Severity and progression. Highly variable — from severe infantile forms (bedridden in the first year, scissoring of legs, severe frontal lobe epilepsy) to mild late‑onset forms with preserved ambulation into adulthood. The course is generally slowly progressive. One large consanguineous family with an identical splicing genotype (c.-20+1G>C) displayed striking intrafamilial variability: "The 3 youngest of branch A were bedridden by their first year because of permanent scissoring of their legs and had severe frontal lobe epilepsy. The single patient from branch B was the least affected, being able to walk until 12 years of age and had no epilepsy" (PMID: 23143715).

Quality‑of‑life impact. Severe forms cause profound motor and cognitive disability with loss of independent ambulation, communication difficulty, and dependence for daily activities; mild forms (SPG44) primarily affect gait with relatively preserved cognition. No disease‑specific EQ‑5D/SF‑36 data are available (ultra‑rare disease).

4. Genetic / Molecular Information

Causal gene. GJC2 (HGNC; formerly GJA12), encoding connexin 47 (Cx47 / connexin 46.6), a gap‑junction protein expressed by oligodendrocytes. The gene was mapped by genome‑wide linkage in a consanguineous PMLD family to chromosome 1q41–q42: "This region harbors the GJA12 gene, which encodes gap junction protein alpha 12 (or connexin 46.6)" (PMID: 15192806). Modern annotation places GJC2 at 1q42.13.

Pathogenic variant spectrum. HLD2 variants span missense, nonsense, frameshift, splice‑site, and non‑coding promoter classes:

Variant Type Phenotype Source
p.G236S Missense PMLD1 (recessive) PMID: 16707726
L281fs285X; P131fs144X Frameshift/truncating PMLD1 PMID: 16707726
p.P87S, p.Y269D, p.M283T Missense (ER‑retained) PMLD1 (severe) PMID: 35276347
c.-167A>G (promoter, SOX10 site) Regulatory PMLD1 (founder) PMID: 21959080
c.-20+1G>C Splice site PMLD1 (variable) PMID: 23143715
c.1096dupG (p.D366Gfs*126) Frameshift PMLD1 PMID: 34840390
p.I33M Missense (WT‑like trafficking) SPG44 (mild) PMID: 19056803; PMID: 35276347
p.V274L (c.820G>C) Missense Late‑onset ataxia/parkinsonism PMID: 31431325
p.G40S; p.R244P Missense GJC2‑related (functional uncoupling) PMID: 40493033

Variant classification & functional consequence. HLD2‑causing alleles are generally classified pathogenic/likely pathogenic (ACMG), and the unifying functional mechanism is loss of function — either through truncation, ER retention/mistrafficking, or loss of channel coupling. "Prior studies in cell lines have shown that PMLD1 mutants such as p.P87S display defective protein trafficking, intracellular retention in the ER and loss-of-function" (PMID: 35276347). Molecular‑dynamics work shows p.G40S modifies the pore‑lining α‑helix (predicting channel closure) and p.R244P disrupts extracellular β‑sheets and membrane electrostatics (PMID: 40493033).

Allelic series (genotype determines severity). GJC2 produces three CNS phenotypes of graded severity plus a non‑CNS dominant phenotype: "Mutations in GJC2 (Cx47)... cause three disorders: a severe early onset dysmyelinating disorder, Pelizaeus-Merzbacher-Like disease (PMLD1 or HLD2); hereditary spastic paraplegia (SPG44), which has a milder phenotype and later onset; and a subclinical leukodystrophy" (PMID: 28545922).

Modifier genes. Not formally identified; allele identity is the primary determinant of severity. Astrocytic Cx43 is mechanistically coupled to Cx47 stability (see §6).

Allele frequency. GJC2 pathogenic alleles are rare in gnomAD; specific founder alleles (c.-167A>G) are enriched in Pakistani‑origin populations. Precise carrier frequencies are not well established for this ultra‑rare disorder.

Epigenetic / chromosomal abnormalities. No recurrent epigenetic signature or large chromosomal rearrangement is associated with HLD2; the promoter c.-167A>G acts by disrupting a SOX10 transcription‑factor binding site rather than by methylation change. No aneuploidy/translocation mechanism.

5. Environmental Information

HLD2 is a purely genetic disorder. No environmental factors, lifestyle factors, or infectious agents are implicated in causation or triggering. The one physiologically relevant "environmental" modulator is neuronal activity: oligodendrocyte connexins buffer K⁺ released during neuronal firing, and loss of this buffering produces activity‑dependent myelin vacuolation — an intrinsic gene–physiology interaction, not an exogenous exposure (PMID: 17065440). Case reports note that febrile illness/status epilepticus may unmask or modify the clinical course of hypomyelinating leukodystrophies, but this is non‑specific (PMID: 41484385).

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

  1. Biallelic loss-of-function mutation in GJC2 (truncating, missense, splice, or SOX10-binding promoter variant) leads to absent, truncated, or misfolded connexin 47 protein, or (for the promoter allele) reduced oligodendrocyte transcription.
  2. For severe missense alleles (p.P87S, p.Y269D, p.M283T), misfolded Cx47 is retained in the endoplasmic reticulum, which results in activation of the unfolded protein response (UPR) and apoptotic pathways in oligodendrocytes (demonstrated in primary oligodendrocytes) (PMID: 35276347).
  3. In parallel (all LoF alleles), failure of Cx47 to reach the membrane results in loss of heterotypic Cx47(oligodendrocyte)–Cx43(astrocyte) gap junctions, which uncouples the panglial syncytium (oligodendrocyte‑to‑astrocyte coupling lost) (PMID: 14681048; PMID: 19056803).
  4. Panglial uncoupling impairs spatial buffering of extracellular K⁺ released during neuronal activity (a role shared with Kir4.1), which leads to activity‑dependent osmotic/ionic stress on myelin (PMID: 17065440).
  5. The combination of oligodendrocyte loss/stress and ionic dysregulation results in failure of normal myelin deposition (hypomyelination) plus myelin vacuolation and, in models, astrogliosis and microglial activation (demonstrated in mouse; inferred for human) (PMID: 25524707).
  6. Deficient CNS myelination leads to impaired saltatory conduction in central white‑matter tracts (optic, cerebellar, corticospinal), which results in the clinical cascade: nystagmus → cerebellar ataxia → spasticity, with cognitive impairment and (in some) peripheral neuropathy (PMID: 21871435; PMID: 15192806).

Branch (severity-determining): Alleles with WT-like trafficking (e.g., p.I33M) retain partial function → milder late-onset SPG44 phenotype with no UPR/apoptosis; ER-retained alleles → severe infantile PMLD1 (PMID: 35276347).

Supporting detail

GJC2 LoF mutation
      │
      ├── (severe missense) ── ER retention ── UPR ── oligodendrocyte apoptosis
      │                                                        │
      └── loss of membrane Cx47 ── loss of Cx47–Cx43 ──────────┤
                   heterotypic gap junctions   │
                           │                   ▼
                   panglial uncoupling ── oligodendrocyte loss/stress
                           │                   │
                   impaired K+ spatial ────────┤
                   buffering (±Kir4.1)         ▼
                           │          HYPOMYELINATION + myelin vacuolation
                           ▼                   │
                   activity-dependent ─────────┘
                   myelin injury               ▼
                              Impaired central conduction
                                      │
               Nystagmus → ataxia → spasticity, cognitive impairment
  • Molecular pathways / cellular processes: gap‑junction intercellular communication (GO:0007267); unfolded protein response (GO:0030968); apoptotic process (GO:0006915); potassium ion homeostasis / spatial buffering (GO:0055075); myelination (GO:0042552).
  • Protein dysfunction: misfolding and ER retention; loss of channel coupling; disruption of pore‑lining helix and extracellular β‑sheet domains (PMID: 40493033).
  • Astrocyte–oligodendrocyte interdependence: oligodendrocytic Cx47 phosphorylation and stability depend on astrocytic Cx43 expression; Cx43 loss reduces Cx47 protein (post‑translational), explaining phenotypic convergence of Cx43/Cx32 and Cx32/Cx47 double knockouts (PMID: 23637189).
  • Immune involvement: secondary — astrogliosis and microglial activation in white‑matter tracts are downstream responses, not autoimmunity (PMID: 22649229).
  • Cell types (CL): oligodendrocyte (CL:0000128); astrocyte (CL:0000127); microglial cell (CL:0000129).
  • Subcellular compartments (GO CC): gap junction (GO:0005921); endoplasmic reticulum (GO:0005783); plasma membrane (GO:0005886); myelin sheath (GO:0043209).

7. Anatomical Structures Affected

  • Primary organ / system: central nervous system — brain and spinal cord white matter (UBERON:0002316 white matter; UBERON:0000955 brain). Body system: nervous system (UBERON:0001016).
  • Specific sites: cerebral white matter, corpus callosum (UBERON:0002336), cerebellum/cerebellar peduncles (ataxia), corticospinal/pyramidal tracts (spasticity), optic nerve (nystagmus; early vacuolation in models), internal capsule, subcortical and periventricular white matter (hyperintense on T2 MRI) (PMID: 31431325).
  • Secondary involvement: peripheral nerve — reduced motor/sensory nerve conduction velocities indicate an associated demyelinating peripheral neuropathy; GJA12 transcripts are detectable in human sciatic and sural nerve (PMID: 15192806).
  • Tissue / cell level: nervous tissue; myelinating oligodendrocytes (CL:0000128) are the primary affected cell, with secondary reactive astrocytes (CL:0000127) and microglia (CL:0000129).
  • Subcellular: gap junctions, endoplasmic reticulum, and the myelin sheath (see §6).
  • Lateralization: bilateral and symmetric white‑matter involvement (characteristic of leukodystrophies).

8. Temporal Development

  • Onset: congenital/early‑infantile for the severe classic form — nystagmus within the first 6 months of life; insidious onset. Mild allelic forms (SPG44, p.V274L) are late‑onset, presenting in adolescence or adulthood (PMID: 21871435; PMID: 19056803; PMID: 31431325).
  • Progression pattern: chronic, slowly progressive; not relapsing‑remitting. Severe forms reach bedridden status within the first year; milder forms preserve ambulation into adulthood.
  • Stages: early (nystagmus, hypotonia, delay) → intermediate (ataxia, emerging spasticity) → advanced (spastic tetraparesis, cognitive decline, loss of ambulation).
  • Disease duration: lifelong/chronic.
  • Critical period: myelination occurs maximally in infancy/early childhood, defining a developmental window of vulnerability — and, by extension, the therapeutic window observed in mouse gene therapy (benefit when delivered at postnatal day 10) (PMID: 28100454).
  • Remission: none spontaneous; nystagmus may partially improve over time while motor signs progress.

9. Inheritance and Population

  • Inheritance: autosomal recessive for the CNS phenotypes (PMLD1/HLD2, SPG44, subclinical leukodystrophy). The distinct lymphedema phenotype is autosomal dominant (see Pleiotropy) (PMID: 15192806; PMID: 40720769).
  • Penetrance: generally high for biallelic severe alleles, but incomplete/reduced penetrance is documented for some leukodystrophy genotypes. In a population‑screening + EHR study of 210,983 individuals, "we identified 9 individuals with genotypes previously reported to result in leukodystrophy, but none of whom had clinical symptoms or MRI" findings — consistent with the recognized GJC2 "minimal/subclinical leukodystrophy" allele (PMID: 42465930).
  • Expressivity: markedly variable, both inter‑ and intra‑familial, even on identical genotypes (PMID: 23143715).
  • Anticipation / mosaicism: not a feature (no repeat expansion); germline mosaicism not characteristically reported.
  • Founder effect / consanguinity: a founder promoter mutation (c.-167A>G) occurs on a shared haplotype in Pakistani‑origin families and accounts for ~29% of reported GJC2‑PMLD patients; consanguinity is prominent across reported families (PMID: 21959080).
  • Epidemiology: ultra‑rare. HLD2 is a small, GJC2‑attributable subset of hypomyelinating leukodystrophies; GJC2 mutations were found in only 3 of 10 PMLD families in one series, underscoring both rarity and genetic heterogeneity (PMID: 16707726). Collective pediatric‑onset leukodystrophy mortality provides context: "An estimated 1.513 per 1,000,000 0-17 year old's died of these LDs at average age 5.2 years and 0.194 for those ≥18 at an average age of 42.3 years" (PMID: 33960638).
  • Sex ratio: ~1:1 (autosomal). Geographic distribution of variants: founder promoter allele enriched in Pakistani‑origin populations; cases reported from Italy, Pakistan, Saudi Arabia, Iran, Turkey, China.

10. Diagnostics

Diagnostic approach. The modern strategy combines MRI pattern recognition with next-generation sequencing: "MRI pattern recognition can provide a clinical diagnosis in many patients. Next-generation sequencing provides a definitive diagnosis in 80-90% of patients" with hypomyelinating leukodystrophies (PMID: 33324001).

  • Neuroimaging (MRI): the pivotal signature is hypomyelination — "diffuse, persistent T2/FLAIR hyperintensity with relative temporal stability and absent enhancement" — distinguishing it from demyelination (confluent, progressive, enhancing lesions) (PMID: 42468917). Symmetric hyperintensity of internal capsule, subcortical and periventricular white matter is seen (PMID: 31431325).
  • Genetic testing: WES/WGS or hypomyelinating‑leukodystrophy gene panels including GJC2; single‑gene GJC2 testing (must cover the non‑coding promoter, as c.-167A>G is missed by routine coding‑exon screening) (PMID: 21959080). Molecular diagnosis distinguishes PMLD1 (biallelic GJC2) from X‑linked PMD (PLP1).
  • Electrophysiology: nerve conduction studies may show reduced motor/sensory conduction velocities (peripheral demyelination); evoked potentials may be abnormal (PMID: 15192806).
  • Biomarkers / labs: no specific biochemical/metabolic biomarker; this is a key feature distinguishing hypomyelinating from metabolic (e.g., metachromatic) leukodystrophies. Diagnosis is imaging‑ and genetics‑based.
  • Differential diagnosis: X‑linked PMD (PLP1), POLR3‑related (4H) leukodystrophy, HSPD1 (MitCHAP‑60), MAG‑related PMD‑like disease, RARS1, TUBB4A, oculodentodigital dysplasia (GJA1), and other HLDs — differentiated by MRI pattern and gene panel (PMID: 27405012; PMID: 26179919; PMID: 39322379).
  • Screening: carrier/cascade testing within affected consanguineous families; prenatal and preimplantation genetic diagnosis are feasible once the familial variant is known (PMID: 34840390).

11. Outcome / Prognosis

  • Survival / mortality: variable and severity‑dependent. Severe infantile HLD2 carries significant morbidity and shortened survival; collective pediatric leukodystrophy death occurs at an average age of 5.2 years in U.S. death‑certificate data, whereas milder/adult‑onset leukodystrophy deaths occur much later (average 42.3 years) (PMID: 33960638). Mild allelic forms (SPG44) are compatible with survival into adulthood with preserved ambulation (PMID: 19056803).
  • Morbidity / disability: severe forms cause spastic tetraparesis, loss of independent ambulation, cognitive impairment, hearing and visual disability, and seizures — lifelong dependence for care. ICF domains of mobility, communication, and self‑care are heavily affected.
  • Complications: aspiration, contractures, epilepsy (frontal lobe seizures in severe forms), feeding difficulty, and infections secondary to immobility.
  • Recovery potential: none without disease‑modifying therapy; the disorder is chronic and (slowly) progressive.
  • Prognostic factors: variant class/allele identity is the dominant prognostic factor — ER‑retained severe missense and truncating alleles predict early severe disease; WT‑like trafficking alleles predict mild late‑onset disease. Earlier onset and presence of epilepsy portend worse outcome (PMID: 35276347; PMID: 23143715).

12. Treatment

No disease-modifying therapy is currently approved. Management is supportive and symptomatic.

  • Supportive / rehabilitative care (NCIT: Supportive Care; Rehabilitation Therapy): physical, occupational, and speech therapy; spasticity management (e.g., baclofen, botulinum toxin); antiepileptic drugs for seizures (e.g., levetiracetam); management of nystagmus, hearing, and nutrition; orthopedic management of contractures (PMID: 41484385; PMID: 37090362).
  • Experimental — gene therapy (preclinical): oligodendrocyte‑targeted AAV delivering Cx47 under the myelin basic protein promoter (AAV.MBP.Cx47myc) produced lasting oligodendrocyte‑specific expression and benefit in the HLD2 mouse model: "Application of this oligodendrocyte-targeted somatic gene therapy at postnatal Day 10 in groups of double knockout mice, a well characterized model of hypomyelinating leukodystrophy-2, resulted in significant improv[ement]" (PMID: 28100454). Transgenic re‑expression of oligodendrocyte connexin (hCx32) rescued the dKO phenotype, confirming a cell‑autonomous, correctable loss‑of‑function mechanism (PMID: 25524707). These remain preclinical; no human trials for HLD2.
  • Pharmacogenomics: not applicable (no genotype‑guided drug therapy established).
  • Note on cell/gene therapy context: autologous hematopoietic stem‑and‑progenitor‑cell gene therapy is approved for metachromatic leukodystrophy (a metabolic, demyelinating leukodystrophy) but is not applicable to HLD2 (PMID: 42431052).

13. Prevention

  • Primary prevention: not possible at the population level (monogenic). Genetic counseling for consanguineous families and at‑risk couples is central; carrier identification allows informed reproductive choices.
  • Secondary prevention / early detection: cascade carrier testing within affected families; prenatal and preimplantation genetic diagnosis once the familial GJC2 variant is known (PMID: 34840390).
  • Carrier screening: expanded carrier screening is particularly relevant in populations with consanguinity and the founder promoter allele (c.-167A>G), which routine coding screening can miss (PMID: 21959080).
  • Immunization / public health / environmental interventions: not applicable.
  • Tertiary prevention: anticipatory management of complications (seizures, contractures, aspiration) to limit morbidity.

14. Other Species / Natural Disease

  • Taxonomy / orthologs: Gjc2 is conserved in mouse (Mus musculus, NCBI Taxon:10090; gene Gjc2/Cx47) and other mammals; the human–mouse ortholog underpins disease modeling.
  • Natural disease in other species: no well‑characterized naturally occurring Cx47/GJC2 leukodystrophy in companion animals or wildlife is documented in the reviewed literature.
  • Evolutionary conservation: the oligodendrocyte–astrocyte connexin coupling architecture (Cx47/Cx32 in oligodendrocytes; Cx43/Cx30 in astrocytes) is conserved across mammals, which is why mouse knockouts recapitulate human white‑matter pathology (PMID: 14681048; PMID: 12805295).
  • Transmission / zoonosis: not applicable (non‑infectious genetic disease).

15. Model Organisms

The mouse is the principal model; HLD2 pathology requires compound connexin deficiency because of functional redundancy.

Model Type Key phenotype Source
Cx47‑null (EGFP reporter) Knockout Mild; vacuolated myelin, especially optic nerve PMID: 12805295
Cx32/Cx47 double‑KO Double knockout Severe CNS demyelination from ~1 month, action tremor, severe motor impairment, death ~51 days — primary HLD2 model PMID: 25524707; PMID: 12805295
Cx30/Cx47 double‑KO Double knockout Panglial uncoupling, myelin vacuolation, ~40% death by 42–90 days, astrogliosis/microgliosis PMID: 22649229
Cx47^M282T knock‑in (human p.M283T ortholog) Knock‑in >80% reduction in glial network coupling; severe myelin defects only when combined with Cx32 loss PMID: 21750683
Cx43/Cx32 double‑KO Double knockout Loss of Cx47 stability/phosphorylation → phenocopies Cx32/Cx47 dKO PMID: 23637189

Phenotype recapitulation: double‑knockout and knock‑in models faithfully reproduce the human hypomyelination/vacuolation, astrogliosis, and motor phenotype, and demonstrated the cell‑autonomous loss‑of‑function mechanism via rescue experiments (PMID: 25524707). The single Cx47‑null mouse under‑recapitulates severe human disease (compensatory Cx32), a key model limitation. Research applications: mechanistic dissection of panglial coupling and K⁺ buffering, and preclinical testing of oligodendrocyte‑targeted gene therapy (PMID: 28100454; PMID: 17065440). Cellular models: primary oligodendrocytes expressing PMLD1 vs SPG44 mutants revealed allele‑specific ER retention/UPR/apoptosis (PMID: 35276347).

GJC2 Pleiotropy (cross-cutting)

A defining feature of this gene is its four‑phenotype allelic series, which must be captured in any knowledge‑base entry:

Phenotype Inheritance Severity Mechanistic note
PMLD1 / HLD2 Autosomal recessive Severe, infantile ER‑retained / truncating LoF; UPR + apoptosis
SPG44 (spastic paraplegia 44) Autosomal recessive Mild, late‑onset Hypomorphic alleles (p.I33M) with WT‑like trafficking
Subclinical / minimal leukodystrophy Autosomal recessive Minimal/none (reduced penetrance) Partial function
Hereditary lymphedema type IC (four‑limb primary lymphedema; OMIM 613480) Autosomal dominant Variable Cx47 in lymphatic endothelium/valves; distinct non‑CNS LoF

"primary human lymphedema is linked to loss-of-function mutations in Cx47 or Cx43" (PMID: 40720769); GJC2/Cx47 was "the second connexin gene associated with a lymphoedema phenotype after the recent publication of GJC2 (connexin 47) as a cause of four limb lymphoedema" (PMID: 23550541); and a Chinese pedigree showed "autosomal dominant generalized lymphedema affecting all four limbs" with a GJC2 variant (PMID: 41530801).

Evidence Base

PMID Title / relevance Supports
15192806 Mutations in GJA12 (connexin 46.6) cause PMLD — gene discovery, 1q41‑q42 mapping, peripheral myelination Causal gene, locus, peripheral neuropathy
16707726 GJA12 mutations in recessive hypomyelinating leukoencephalopathy AR LoF causation; rarity/heterogeneity (3/10 families)
35794704 Novel GJC2 mutation in HLD2 Disease definition as recessive GJC2/GJA12 disease
28545922 Diseases of connexins in myelinating glia Allelic series (PMLD1/SPG44/subclinical)
35276347 UPR activation by Cx47 mutations ER retention, UPR, apoptosis; allele‑specific severity
40493033 MD simulation of GJC2 mutants Structural mechanism of channel loss
14681048 Astrocyte/oligodendrocyte connexins of glial syncytium Heterotypic Cx47–Cx43 panglial coupling
17065440 Oligodendrocyte gap junctions & K⁺ buffering K⁺ spatial buffering role
19056803 HSP is a novel phenotype for GJA12/GJC2 SPG44 mild allelic end; Cx47–Cx43 disruption
21871435 Gap junctions in CNS disorders Cardinal temporal clinical sequence
23143715 PMLD family with variable phenotype & splicing mutation Intrafamilial variable expressivity
31270756 Novel GJC2 mutations in PMLD Broader neurological phenotype
21959080 Promoter mutation common in GJC2‑PMLD Founder SOX10‑site promoter allele (~29%)
33324001 Hypomyelinating leukodystrophies — myelin biology MRI + NGS diagnostic yield 80–90%
42468917 MRI in leukodystrophies Hypomyelination imaging definition
25524707 Transgenic Cx32 rescue in dKO HLD2 mouse model; cell‑autonomous rescue
28100454 Oligodendrocyte‑targeted gene therapy AAV‑Cx47 preclinical benefit
22649229 Panglial gap junctions maintain myelin Cx30/Cx47 dKO pathology
23637189 Cx47 stability depends on astrocytic Cx43 Astrocyte–oligodendrocyte interdependence
21750683 Cx47^M282T knock‑in mouse Loss of channel function = PMLD1 cause
12805295 Cx47‑null mouse Oligodendrocytic expression; myelin vacuolation
40720769 Endothelial connexins in lymphatic valves Cx47 LoF → primary lymphedema
23550541 GJA1 in ODDD & lymphedema GJC2 first connexin linked to four‑limb lymphedema
41530801 GJC2/OBSCN in lymphedema pedigree AD four‑limb lymphedema
33960638 US leukodystrophy death rates Mortality rate/age context
42465930 Leukodystrophy penetrance (population + EHR) Incomplete penetrance / subclinical phenotype

Evidence source types: human clinical/genetic (family and cohort studies, population screening), model organism (mouse knockouts/knock‑ins and gene therapy), in vitro (primary oligodendrocytes, cell lines), and computational (molecular dynamics). The causal‑gene and allelic‑series claims rest on strong converging human genetic + functional evidence; the detailed step‑by‑step pathophysiology (K⁺ buffering failure → vacuolation) is best demonstrated in mouse/in‑vitro systems and is inferred for the human disease by homology.

Limitations and Knowledge Gaps

  1. Rarity limits epidemiology. No HLD2‑specific prevalence/incidence figures exist; estimates are inferred from the GJC2‑attributable subset of hypomyelinating leukodystrophies and from pooled leukodystrophy mortality data.
  2. Genotype–phenotype map is incomplete. Allele identity clearly drives severity, but quantitative penetrance/expressivity per variant is not established, and modifier loci are unknown.
  3. Human pathophysiology is largely inferred from mouse. The K⁺‑buffering/vacuolation chain and UPR/apoptosis contributions are demonstrated in models and in vitro; direct human tissue confirmation is limited.
  4. No human therapeutics. Gene therapy is preclinical; there are no completed clinical trials, no validated biomarkers of progression, and no standardized outcome measures for HLD2 specifically.
  5. Peripheral nervous system involvement is reported (reduced NCV) but under‑characterized relative to CNS disease.
  6. Non‑coding variants (e.g., promoter c.-167A>G) are under‑ascertained by standard coding‑exon panels, risking missed diagnoses.

Proposed Follow-up Experiments / Actions

  1. Build a variant‑stratified natural‑history registry linking specific GJC2 alleles (truncating vs ER‑retained missense vs hypomorphic) to onset, milestones, MRI trajectory, and survival to quantify penetrance/expressivity.
  2. Standardize diagnostics to include the GJC2 promoter/SOX10‑binding region (c.-167A>G) in panels, especially for consanguineous and Pakistani‑origin families; pair MRI pattern recognition with targeted NGS.
  3. Advance oligodendrocyte‑targeted AAV‑Cx47 gene therapy from the double‑KO mouse toward IND‑enabling studies, defining the therapeutic window relative to the human myelination period.
  4. Develop iPSC‑derived oligodendrocyte and organoid models from patient alleles to map, per variant, the balance of channel‑coupling loss vs ER‑retention/UPR, enabling allele‑specific therapeutic triage (e.g., proteostasis modulators for ER‑retained mutants).
  5. Characterize the peripheral neuropathy systematically (nerve conduction, nerve imaging) across genotypes.
  6. Expanded carrier screening / genetic counseling programs in high‑consanguinity populations, with cascade testing and PGD options for known familial variants.

Report compiled from 13 confirmed findings and 56 reviewed papers across 5 investigation iterations. Ontology suggestions: MONDO:0012125; HGNC GJC2; GO:0007267, GO:0030968, GO:0006915, GO:0055075, GO:0042552; GO CC: 0005921, 0005783, 0043209; CL:0000128, CL:0000127, CL:0000129; UBERON:0002316, 0000955, 0002336, 0001016.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.3.0.

Outcome Count
References checked 34
Resolved 34
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 1
Quoted claims found in source 1
Quoted claims not found in source 0
References weighed for topical relevance 34
On topic 23
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 29
Resolved 27
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 2
Terms whose name was checked 17
Terms named correctly 3
Terms named as a different term 13
Terms whose name is worth a second look 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0012125 (3 mentions) - the report calls it "MONDO"; MONDO calls it leukodystrophy, hypomyelinating, 2
  • HP:0000639 (1 mention) - the report calls it "Clinical sign (ocular)"; HP calls it Nystagmus
  • HP:0001251 (1 mention) - the report calls it "Clinical sign"; HP calls it Ataxia
  • HP:0001257 (1 mention) - the report calls it "Clinical sign"; HP calls it Spasticity
  • HP:0001263 (1 mention) - the report calls it "Sign"; HP calls it Global developmental delay
  • HP:0001249 (1 mention) - the report calls it "Sign"; HP calls it Intellectual disability
  • HP:0000407 (1 mention) - the report calls it "Lab/clinical"; HP calls it Sensorineural hearing impairment
  • HP:0000504 (1 mention) - the report calls it "Sign"; HP calls it Abnormality of vision
  • HP:0001250 (1 mention) - the report calls it "Sign"; HP calls it Seizure
  • HP:0002061 (1 mention) - the report calls it "Sign"; HP calls it Lower limb spasticity
  • HP:0000762 (1 mention) - the report calls it "Lab"; HP calls it Decreased nerve conduction velocity
  • GO:0007267 (2 mentions) - the report calls it "Molecular pathways / cellular processes: gap‑junction intercellular communication"; GO calls it cell-cell signaling**
  • UBERON:0002336 (1 mention) - the report calls it "Specific sites: cerebral white matter, corpus callosum"; UBERON calls it corpus callosum**

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • CL:0000129 (3 mentions) - the report calls it "microglia"; CL calls it microglial cell, and lists "microglia" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, Taxon.